PMID- 26868135
OWN - NLM
STAT- MEDLINE
DCOM- 20170123
LR  - 20170123
IS  - 1827-1839 (Electronic)
IS  - 0392-9590 (Linking)
VI  - 35
IP  - 2
DP  - 2016 Apr
TI  - Sulodexide reduces the inflammatory reaction and senescence of endothelial cells 
      in conditions involving chronic venous disease.
PG  - 140-7
AB  - BACKGROUND: According to previous studies, sulodexide suppresses intravascular 
      inflammation when used in patients with chronic venous disease (CVD). In the 
      current study, we tested the effect of prolonged in vitro exposure of human 
      venous endothelial cells to the serum from patients with CVD, examining the 
      function of these cells and how it is modified when these cells are 
      simultaneously exposed to sulodexide. METHODS: Human umbilical venous cells 
      (HUVEC) were cultured in standard medium (control), in medium supplemented with 
      5% serum pooled from CVD patients (CVD-serum) or in medium from CVD patients who 
      were treated with sulodexide (CVD-serum-SUL). The synthesis of interleukin-6 
      (IL-6), monocyte chemoattractant protein -1(MCP-1) and soluble intercellular 
      adhesion molecule - 1 (s-ICAM-1) were studied at the beginning of incubation and 
      were measured after 9 and 15 days of exposure to the studied media. The 
      concentration of IL-6 after cell stimulation by interleukin -1 (IL-1) was also 
      measured. In a subsequent part of the experiment, the effect of the studied sera 
      on the in vitro replicative ageing of HUVEC was evaluated. A total of 15 passages 
      of the cell culture were performed and both the PDT (population doubling time) 
      and the cell hypertrophy were assessed. RESULTS: The concentrations of Il-6, 
      MCP-1, and ICAM-1 gradually increased in the supernatants containing 5% CVD serum 
      compared with the control medium. In the supernatants obtained after cell 
      incubation with serum from sulodexide treated patients, the increase in 
      concentrations of IL-6, MCP-1 and ICAM-1 was significantly less than the control. 
      Release of IL-6 after stimulation with IL-1 (100 pg/mL) was the highest in the 
      CVD-serum group: 3540+/-670 pg/105 cells vs. 1850+/-540 pg/105 cells in the control 
      (P<0.01 vs. CVD-serum) and 2320 +/-430 pg/105 cells in CVD-serum-SUL (P<0.02 vs. 
      CVD-serum). PDT was significantly longer in the cells incubated with CVD serum 
      compared with the control group, and PDT was reduced when serum from sulodexide 
      treated patients was used. The cells became senescent in the presence of CVD 
      serum, but the cells obtained from patients at the end of 8 weeks of treatment 
      with sulodexide showed a much weaker inflammatory phenotype than the CVD group. 
      CONCLUSIONS: Chronic in vitro exposure of HUVEC to medium supplemented with CVD 
      patient serum induces an inflammatory phenotype. Sulodexide treatment 
      significantly reduces that effect and slows HUVEC senescence in the milieu of CVD 
      serum.
FAU - Urbanek, Tomasz
AU  - Urbanek T
AD  - Department of General and Vascular Surgery, Medical University of Silesia, 
      Katowice, Poland - urbanek.tom@interia.pl.
FAU - Krasinski, Zbigniew
AU  - Krasinski Z
FAU - Suminska-Jasinska, Katarzyna
AU  - Suminska-Jasinska K
FAU - Baum, Ewa
AU  - Baum E
FAU - Borej-Nowicka, Grazyna
AU  - Borej-Nowicka G
FAU - Begier-Krasinska, Beata
AU  - Begier-Krasinska B
FAU - Breborowicz, Andrzej
AU  - Breborowicz A
LA  - eng
PT  - Journal Article
DEP - 20160211
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
SB  - IM
MH  - Aged
MH  - Cells, Cultured
MH  - Chemokine CCL2/*blood
MH  - Chronic Disease
MH  - Endothelial Cells/*drug effects
MH  - Glycosaminoglycans/*pharmacology
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Intercellular Adhesion Molecule-1/*blood
MH  - Interleukin-6/*blood
MH  - Middle Aged
MH  - Vascular Diseases/*blood
EDAT- 2016/02/13 06:00
MHDA- 2017/01/24 06:00
CRDT- 2016/02/13 06:00
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2017/01/24 06:00 [medline]
AID - R34Y9999N00A16021104 [pii]
PST - ppublish
SO  - Int Angiol. 2016 Apr;35(2):140-7. Epub 2016 Feb 11.